1
|
Costa EC, Artigas L, Martinez-Cardús A, López A, Camprodon MC. 141P Unveiling the likely pharmacological mechanisms of brigatinib on brain metastasis in ALK+ patients with non-small cell lung cancer: A systems biology and artificial intelligence-based approach. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00396-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
2
|
Ahn MJ, Kim SW, Costa EC, Rodríguez L, Oliveira J, Insa Molla M, Majem M, Costa L, Su WC, Lee K, Yang JH, Spigel D, Cho E, D'Arcangelo M, Campelo MG, Delmonte A, Mitchell P, Achour I, Subramaniam D, Felip E. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
3
|
Ghiringhelli F, Barre P, Pichon E, Ponce Aix S, Juan Vidal O, Carcereny Costa E, Sethi T, Lindmark B, MacKinnon A, Aslanis V, Phung D, Jensen P, Rajiwate Z, Ross G, Basse L. 1192TiP GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Garcia Campelo M, Domine Gomez M, De Castro Carpeno J, Moreno Vega A, Ponce Aix S, Arriola E, Carcereny Costa E, Majem Tarruella M, Huidobro Vence G, Esteban Gonzalez E, Fuentes Pradera J, Ortega Granados A, Guillot Morales M, Massuti Sureda B, Vila Martinez L, Blasco Cordellat A, Fajardo C, Crama L, Lerones Laborda N, Cobo Dols M. 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Ponce Aix S, Carcereny Costa E, Bosch-Barrera J, Felip Font E, Guirado M, Coves Sarto J, Majem Tarruella M, Juan Vidal O, Dalmau Portulas E, Diz P, Ortega Granados A, Domine Gomez M, Blasco Cordellat A, Mosquera Martinez J, Sala Gonzalez M, Dorta M, Calvo de Juan V, Zugazagoitia J, Enguita A, Paz-Ares L. 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
6
|
Martinez-Marti A, Majem M, Barlesi F, Carcereny Costa E, Chu Q, Monnet I, Sanchez A, Dahkil S, Camidge D, He P, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Herbst R. LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2121] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Krebs M, Helland Å, Carcereny Costa E, Arriola Aperribay E, Dómine Gómez M, Trigo Pérez J, Thompson J, Strauss J, Ortega Granados A, Felip E, Schmidt E, Chisamore M, Madeleine N, Rayford A, Lorens K, Siddiqui A, Gabra H, Nautiyal J, Micklem D, Lorens J, Spicer J. OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Calvo V, Carcereny Costa E, Guirado M, Ortega Granados A, Lopez Castro R, Rodriguez-Abreu D, Garcia Campelo R, del Barco Morillo E, Juan-Vidal O, Camps C, Gonzalez-Larriba J, Domine Gomez M, Trigo Perez J, Cobo Dols M, Cerezo Gonzalez S, Calzas Rodriguez J, Massuti Sureda B, Bosch-Barrera J, Moran T, Provencio Pulla M. 1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Carcereny Costa E, Calvo V, Guirado M, Ortega Granados A, Lopez Castro R, Rodriguez-Abreu D, Mosquera Martinez J, del Barco Morillo E, Juan-Vidal O, Sanchez Hernandez A, Sala Gonzalez M, Blanco Guerrero R, Bernabe Caro R, Alonso R, Garcia Benito C, Oramas Rodriguez J, Diz Tain P, Nogueron Martinez E, Guirao Rubio C, Provencio Pulla M. 1786P Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
10
|
Michels S, Massuti Sureda B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohe C, Rodríguez-Abreu D, Bischoff H, Carcereny Costa E, Corral Jaime J, Insa A, Reck M, Scheffler M, Karachaliou N, Merkelbach-Bruse S, Nogova L, Büttner R, Rosell R, Wolf J. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Carcereny Costa E, Guirado M, Camps Herrero C, Bosch Barrera J, García-Campelo MR, Ortega Granados A, Gonzalez-Larriba J, De Dios Alvare N, Domine Gomez M, Massuti Sureda B, Sala M, Bernabé R, Oramas Rodriguez J, del Barco Morillo E, Padilla A, Aguiar Bujanda D, Cerezo Gonzalez S, Lopez Castro R, Rodriguez Abreu D, Provencio M. Tobacco use in lung cancer (LC) patients (p) in Spain. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Trigo Perez J, Felip E, Brunsvig P, Helland A, Viñolas N, Ponce Aix S, Carcereny Costa E, Domine Gomez M, Arriola E, Garcia Campelo R, Spicer J, Thompson J, Ortega Granados A, Holt R, Lorens J, Shoaib M, Siddiqui A, Schmidt E, Chisamore M, Krebs M. Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Rodriguez Abreu D, Guirado M, Camps Herrero C, Bosch Barrera J, Bernabé R, Casal J, García-Campelo MR, Gonzalez-Larriba J, Massuti Sureda B, Ortega Granados A, Domine Gomez M, Sala M, Padilla A, Del Barco Morillo E, Oramas Rodriguez J, Blanco Guerrero R, Aguiar Bujanda D, López Castro R, Carcereny Costa E, Provencio M. Biomarker testing of lung cancer in Spain. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Angelats L, Garcia Campelo M, Bernabe Caro R, Arriola Aperribay E, Calvo de Juan V, Barba Joaquín A, Vinolas Segarra N, Gil Moreno M, Vilà Martinez L, Juan Vidal O, Vilariño Quintela N, Cobo M, Sais E, Domine Gomez M, Fernandez Nuñez N, Coves Sarto J, Marse Fabregat R, Esteve Gomez A, Rodríguez-Abreu D, Carcereny Costa E. Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Carcereny Costa E, Rodriguez-Abreu D, Guirado M, López-Castro R, Massutí B, Bosch Barrera J, Nogueron Martnez E, Sala Gonzalez M, Domine Gomez M, Del Barco Morillo E, Cerezo Gonzalez S, Dorta Suarez M, Casal Rubio J, Camps C, Muñoz M, de las Peñas R, Ortega dominguez J, Gonzalez-Larriba J, Bernabe Caro R, Provencio Pulla M. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Karachaliou N, Lefterova M, Draper J, Molina MA, Chaib I, Palmero R, Taus A, Viteri S, González Cao M, Majem Tarruella M, Carcereny Costa E, Moran T, Garde Noguera J, Felip Font E, Olsen S, Jackson M, Sampayo M, Faull I, Dix D, Rosell R. Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Palmero R, Taus Á, Majem Tarruella M, Viteri S, Carcereny Costa E, Garde J, Felip Font E, Cassidy C, Dix D, Karachaliou N, Rosell R. Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Remon J, Martinez-Marti A, Carcereny Costa E, Zeron-Medina Cuairan J, Sansano I, Mate J, Pardo N, Cedres S, Navarro A, Martinez de castro A, Moran T, Felip Font E. Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Erasun Lecuona C, Moran Bueno M, Vila L, Teruel I, Angelats L, Ferrando A, Plaja A, Torres P, Lopez E, Muriel R, Muñoz-Marmol A, Mate J, Velarde J, Carcereny Costa E. KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Popat S, Ardizzoni A, Ciuleanu T, Cobo Dols M, Laktionov K, Szilasi M, Califano R, Carcereny Costa E, Griffiths R, Paz-Ares L, Szczylik C, Corral J, Isla D, Jassem J, Appel W, Van Meerbeeck J, Wolf J, Jiang J, Molife L, Felip Font E. Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Erasun Lecuona C, Moran Bueno M, Vila L, Teruel I, Angelats L, Ferrando A, Plaja A, Torres P, Lopez E, Muriel R, Muñoz-Marmol A, Mate J, Velarde J, Carcereny Costa E. KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Peters S, Carcereny Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Eberhardt W, Garassino MC, Rizvi NA, Besse B, Jänne PA, Peters S, Keong Toh C, Kurata T, Carcereny Costa E, Koczywas M, Felip Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson ML. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017. [DOI: 10.1055/s-0037-1598277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- W Eberhardt
- Universitätsklinikum Essen, Ruhrlandklinik, West German Cancer Center, Universität Duisburg-Essen
| | - MC Garassino
- Fondazione Irccs Istituto Nazionale Dei Tumori, Thoracic Oncology Unit
| | - NA Rizvi
- New York-Presbyterian/Columbia University Medical Center
| | - B Besse
- Gustave Roussy, Villejuif France and Paris Sud University
| | | | | | | | - T Kurata
- Kansai Medical University Hirakata Hospital
| | - E Carcereny Costa
- Catalan Institute of Oncology Badalona – Germans Trias I Pujol Hospital Badalona
| | | | | | - J Chaft
- Memorial Sloan Kettering Cancer Center
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Costa EC, Dantas TCB, de Farias Junior LF, Frazão DT, Prestes J, Moreira SR, Ritti-Dias RM, Tibana RA, Duhamel TA. Inter- and Intra-Individual Analysis of Post-Exercise Hypotension Following a Single Bout of High-Intensity Interval Exercise and Continuous Exercise: A Pilot Study. Int J Sports Med 2016; 37:1038-1043. [PMID: 27676151 DOI: 10.1055/s-0042-112029] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Recently, post-exercise blood pressure (BP) has been considered a predictive tool to identify individuals who are responsive or not to BP reductions with exercise training (i. e., "high" and "low responders"). This study aimed to analyze the inter- and intra-individual BP responsiveness following a single bout of high-intensity interval exercise (HIIE) and continuous exercise (CE) in normotensive men (n=14; 24.5±4.2 years). Mean change in BP during the 60 min period post-exercise was analyzed and minimal detectable change (MDC) was calculated to classify the subjects as "low" (no post-exercise hypotension [PEH]) and "high responders" (PEH occurrence) following each exercise protocol (inter-individual analysis). The MDC for systolic and diastolic BP was 5.8 and 7.0 mmHg. In addition, a difference equal/higher than MDC between the exercise protocols was used to define an occurrence of intra-individual variability in BP responsiveness. There were "low" and "high" PEH responders following both exercise protocols (inter-individual variability) as well as subjects who presented higher PEH following a specific exercise protocol (intra-individual variability between exercise protocols). These results were observed mainly for systolic BP. In summary, PEH is a heterogeneous physiological phenomenon and, for some subjects, seems to be exercise-protocol dependent. Further investigations are necessary to confirm our preliminary findings.
Collapse
Affiliation(s)
- E C Costa
- Department of Physical Education, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - T C B Dantas
- Department of Physical Education, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - L F de Farias Junior
- Department of Physical Education, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - D T Frazão
- Department of Physical Education, Federal University of Rio Grande do Norte, Natal, RN, Brazil
| | - J Prestes
- Department of Physical Education, Federal University of Vale do São Francisco, Petrolina, PE, Brazil
| | - S R Moreira
- Department of Physical Education, Federal University of Vale do São Francisco, Petrolina, PE, Brazil
| | - R M Ritti-Dias
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
| | - R A Tibana
- Health Leisure and Human Performance Research Institute, Faculty of Kinesiology and Recreation Management, University of Manitoba, Winnipeg, MB, Canada
| | - T A Duhamel
- Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada
| |
Collapse
|
25
|
Rocha RMP, Alves AMCV, Lima LF, Duarte ABG, Chaves RN, Brito IR, Costa EC, Bernuci MP, Rosa-e-Silva ACJS, Xu M, Rodrigues APR, Campello CC, Figueiredo JR. Is the mouse follicle culture a good model for the goat with respect to the development of preantral follicles in vitro? Domest Anim Endocrinol 2014; 49:27-30. [PMID: 25010025 DOI: 10.1016/j.domaniend.2014.04.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2014] [Revised: 04/24/2014] [Accepted: 04/25/2014] [Indexed: 10/25/2022]
Abstract
The present study evaluated the efficiency of using 2 culture media developed for mice and for goats in the in vitro preantral follicle culture of each species. Murine and caprine secondary follicles were cultured in vitro with human recombinant follicle-stimulating hormone (murine medium) or with bovine recombinant follicle-stimulating hormone in association with growth hormone (caprine medium). The results showed that murine follicles cultured in caprine medium had lower (P < 0.05) rates of follicular survival and growth, whereas for caprine follicles, these variables were not affected by the type of medium used (P > 0.05). After in vitro maturation, a higher (P < 0.05) number of oocytes that resumed meiosis were observed in the murine medium for both species. In contrast, only in the caprine species estradiol production was significantly superior when the caprine medium was used. Higher progesterone production was observed in the presence of the murine medium only for murine follicles (P < 0.05). In conclusion, murine and caprine preantral follicles cultured under the same in vitro culture medium conditions respond differently; caprine oocytes grown in vitro in the presence of the murine medium show the greatest developmental competence among the tested combinations. Therefore, under the present experimental conditions, the mouse follicle culture has proved be a good model for the development of new culture media for caprine preantral follicles.
Collapse
Affiliation(s)
- R M P Rocha
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil.
| | - A M C V Alves
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - L F Lima
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - A B G Duarte
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - R N Chaves
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - I R Brito
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - E C Costa
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - M P Bernuci
- Department of Obstetrics and Gynecology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - A C J S Rosa-e-Silva
- Department of Obstetrics and Gynecology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - M Xu
- Division of Reproductive Biology and Clinical Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
| | - A P R Rodrigues
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - C C Campello
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| | - J R Figueiredo
- Faculty of Veterinary Medicine, LAMOFOPA, State University of Ceara, Fortaleza, Ceara, Brazil
| |
Collapse
|
26
|
Karachaliou N, Drozdowskyj A, Gimenez-Capitan A, Morales-Espinosa D, Moran T, Costa EC, Cobo M, Domine M, Bover I, Camps C, Pulla MP, Vergnenegre A, Lopez-Vivanco G, Tarruella MM, Viteri S, Sureda BM, Rosell R. Palb2 Mrna Expression As a Predictive and Prognostic Marker in Advanced Non-Small-Cell Lung Cancer (Nsclc) Patients (P) Treated with Cisplatin- Docetaxel Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Massuti B, Jimenez U, Rodriguez Paniagua JM, Pun YW, Cobo M, Carcereny Costa E, Arrabal R, Astudillo J, Barneto IC, De Las Penas R, Baamonde C, Sales G, Gonzalez-Larriba J, Lopez-Vivanco G, Hernando-Trancho F, Pac J, Artal-Cortes A, Rivas J, Rosell R, Sanchez JM. SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Carcereny Costa E, Provencio Pulla M, Cubedo Cervera R, Sánchez Ruiz A, Sánchez Vegazo I, González Hernando C, Cantos Sánchez de Ibargüen B, Espinosa Aunión R. [Patient with double lung lesion and history of renal adenocarcinoma]. Rev Clin Esp 2004; 204:379-80. [PMID: 15274786 DOI: 10.1157/13063532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- E Carcereny Costa
- Servicio de Oncología Médica, Hospital Universitario Puerta de Hierro, Madrid
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Carcereny Costa E, Provencio Pulla M, Cubedo Cervera R, Sánchez Ruiz A, Sánchez Vegazo I, González Hernando C, Cantos Sánchez de Ibargüen B, Espinosa Aunión R. Paciente con doble lesión pulmonar y antecedentes de adenocarcioma renal. Rev Clin Esp 2004. [DOI: 10.1016/s0014-2565(04)71490-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Weigand O, de Souza AZ, Okawara H, Costa EC, Salvatore CA. [Post-mastectomy rehabilitation]. AMB Rev Assoc Med Bras 1982; 28:143-7. [PMID: 6984942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|